Graft-vs-Host Disease: Novel Targets and Breakthrough Therapies
  • CME

In this CME-certified module, review key insights into the latest clinical developments and emerging therapeutic approaches for GVHD, presented by faculty experts Nelson Chao, MD, MBA, and David Miklos, MD, PhD.
Nelson Chao, MD, MBA
David Miklos, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: December 5, 2017 Expiration: December 4, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe current advances in our understanding of the biology of GVHD
  • Discuss the role of new pharmacologic interventions and how they can intersect with the pathogenesis of GVHD
  • Identify ongoing trials of investigational approaches in the prevention and treatment of GVHD to aid referral of patients for study participation

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Incyte

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Nelson Chao, MD, MBA

Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematology Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, North Carolina

Nelson Chao, MD, MBA, has no real or apparent conflicts of interest to report.
David Miklos, MD, PhD

Associate Professor of Medicine
Clinical Director,
Cancer Cell Therapy Program
Division of Blood and Marrow Transplantation
Stanford University
Stanford, California

David Miklos, MD, PhD, has disclosed that he has received consulting fees from Kite Pharma, Novartis, and Pharmacyclics and funds for research support from Genentech, Kite Pharma, and Pharmacyclics.

Staff

Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Terrence Fagan

Associate Managing Editor

Terrence Fagan has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with or at risk of graft-vs-host disease.

Goal

The goal of this activity is to improve participants’ knowledge and competence in applying emerging targeted pharmacologic interventions to prevent or manage GVHD.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 05, 2017, through December 04, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable and fully editable slides highlighting CLL case challenges with data supporting optimal treatment recommendations.

William G. Wierda, MD, PhD Andrew D. Zelenetz, MD, PhD Released: June 27, 2018

In this Expert Analysis of key data from the Hematology 2017 annual meeting, Julie Kanter, MD; Gary Lyman, MD, MPH, FASCO, FRCP (Edin); Keith R. McCrae, MD; and Guy A. Young, MD, discuss the clinical applicability of new findings in nonmalignant hematologic disorders presented at the conference, including sickle cell disease, immune thrombocytopenia, hemophilia A, venous thromboembolism, and aplastic anemia.

Julie Kanter, MD Gary Lyman, MD, MPH, FASCO, FRCP (Edin) Keith R. McCrae, MD Guy A. Young, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 27, 2018 Expiration: February 26, 2019

In this on-demand Webcast of a CCO symposium at ASH 2017, Ranjana Advani, MD, leads an expert panel with Robert W. Chen, MD; Andrew Evens, DO, MSc, FACP; and Pier Luigi Zinzani, MD, PhD, as they review and discuss the latest clinical strategies for managing patients with Hodgkin lymphoma.

Ranjana Advani, MD
Program Director
Robert W. Chen, MD Andrew M. Evens, DO, MSc, FACP Pier Luigi Zinzani, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 24, 2018 Expiration: January 23, 2019

How has the approval of letermovir prophylaxis altered post-HCT CMV management? Here’s my take.

Genovefa A. Papanicolaou, MD Released: January 16, 2018

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?